Healthcare Sector in India Monthly Update October 2012

7/29/2019 Healthcare Sector in India Monthly Update October 2012

http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-october-2012 1/14

Healthcare Sector in India

Monthly Update

October 2012



Top Story

BITS Pilani comes up with 1st indigenous low cost glucometer

BITS Pilani scientists have come up with India’s 1st indigenous glucometer which has passedthe final evaluation test conducted by the Indian Council of Medical Research (ICMR). The

device comes with the unique feature of costing as low as INR 2 per test. The cost thus israted much below of what Indian Health Ministry had promised of developing ‐ a diabetic

testing chip that would cost INR 5 per test. Additionally, the device is capable of providing

speedy results in as less as 10 seconds with 1,000 times lesser blood than what prevailing

lucometers require. Hence the entire procedure from finger pricking to loading the bloodk l

gsample to flashing of the result may ta e up about a minute on y.

The prototype device is expected to be ready by Dec 2012 which will then go through aonth long multi‐centre efficacy study in various labs before it gets rolled out for massm

production.

The huge diabetic population of India will be benefitted since the latest test will not require

repeated use of expensive testing strips due to its cost effectiveness.

News Update

General

SightLife partners

with

L V

Prasad

Eye

Institute

A corneal tissue cutting centre has been established at the Ramayamma International Eye

Bank at L V Prasad Eye Institute (LVPEI) in Hyderabad. The facility is an initiative by the

eattle based global healthcare organization SightLife that has been making efforts toS

improve surgical techniques for better outcomes.

Descemet’s Stripping Endothelial Keratoplasty (DSEK) which is currently being consideredas the most effective treatment for corneal edema is dependent on superior equipments and

trained professionals. The equipments required for lamellar dissection of the donor cornea

requires a host of special equipments that are unavailable in Indian hospitals. SightLife heres making a serious effort by partnering with India based eye banks to provide the less

nvasive and reduced rejection risk treatment to Indians.

i

i Dabur to re-launch 30-Plus

The world’s largest ayurveda company Dabur will be re‐launching its once popular over‐the‐

counter (OTC) revitalize brand ‘30‐Plus’ that it acquired in May 2011. Launched in 1990s, therand fizzed out from the popularity chart as its promoter Ajanta Pharma started

oncentrating in promotion of prescription drugs.

b

c

Healthcare Sector – Monthly Update



The re‐launch of the product has been planned by Dabur with the intention of revamping andexpanding its OTC portfolio by launching new products in emerging therapeutic areas. The

product will be competing with Ranbaxy’s popular brand Revital that has a significant share

n energizer products segment which alone registered a growth rate of 25% in the past inancial year.

if

India’s first indigenous insulin pen

French drug maker Sanofi SA subsidiary Sanofi India Ltd. has given to India its first everlocally manufactured insulin pen. The product branded as AllStar has been manufactured

especially keeping Indian users in mind. The product is not only reusable but is being

aunched at a budget price of INR 650 only that comes within a patient’s affordability. Theroduct will also be made available in the overseas market.

lp

Krishna Hospital to merge with Shalby Hospitals

Yogeshwar Healthcare Ltd, which initiated operation of Ghuma located Krishna Hospital inthe year 2000 gave to Ahmadabad its first corporate hospital. The hospital is in the process

of getting merged with Ahmadabad based Shalby Hospitals. Shalby has acquired a majoritytake of 86% that is being rumored to be valued at INR 750 mn to INR 850 mn. Thes

transaction thus makes Shalby the biggest corporate hospital in Ahmadabad with 450 beds.

On completion of the formalities, Krishna Hospital will be expanded into a 250‐bedded multi‐

pecialty hospital. The upgradation of Krishna Hospital is expected to help in diverting the

atient traffic from Shalby Hospital which faces a perennial shortage of beds.

s

p

SMS Pharmaceuticals sells off manufacturing plant to Mylan

Global healthcare company Mylan Laboratories has bought Hyderabad based SMSPharmaceuticals’ Vishakhapatnam located manufacturing unit for INR 1.73 bn. The proceeds

from the transaction will be used by SMS Pharmaceuticals for clearing off some of its past

ebts, cutting down overhead costs along with upgrading its existing manufacturing facilitiesd

and strengthening its working capital base.

The transaction is expected to improve both the companies’ position in market. On one handSMS Pharmaceuticals would be able to do away with its past debts and strengthen its

urrently operative manufacturing units, and on the other hand Mylan’s acquisition of the

anufacturing unit is an expansion for the generic pharma manufacturer.

c

m

Micro Labs

Ltd.

introduces

Hypotab

Karnataka based Micro Labs Ltd. has penetrated the Indian hypoglycemic market with its

new dextrose drug ‘Hypotab’. The drug has been identified to be suitable for mild tooderate hypoglycemia conditions. The company has invested INR 55 mn for production of

he drug at its Puducherry unit that has an installed capacity of 1mn tabs/month.

m

t




It uses the advanced AbMax technology that helps to pulverize the active ingredient dextroseo about 20 micron particle size for immediate absorption into the blood stream. The

ompany is expecting a turn over of INR 42 mn from this latest addition to its drug portfolio.

t

c

Intas group seeking merger of its group companies

Ahmadabad based Intas Group is seeking to amalgamate 4 group companies for which it has

already filed a petition in the Gujarat High Court. The companies to be amalgamated under

ections 391 to 394 of the Companies Act, 1956, include Intas Pharmaceuticals Ltd., AstornsResearch Ltd., Intas Biopharmaceuticals Ltd. and Celestail Biologicals Ltd.

The parent company will be holding meeting of all shareholders and secured and unsecuredcreditors to get their consent on the amalgamation proposal of the concerned companies.

he consolidation will possibly help in bringing about cost efficiency and enhancement of

evenue through gain in market share.

T

r

Fortis combines luxury and entertainment with hospital

Fortis has forged ahead in the hospital industry by its inauguration of ‘hospital mall’ – theFortis Memorial Research Institute (FMRI) in Gurgaon. The ‘next generation concept

hospital’ houses multi‐specialty hospital with shopping mall that will have 18 retail and food

utlets. The 450 bedded FMRI is equipped with 25 operating rooms along with a full‐fledgedostem‐cell lab.

The Fortis group has clear plans of expanding the facility not only in terms of space but also

facilities. The number of beds is expected to go up to 1,000 and will soon be introducingrobotic surgery and organ transplant facilities. In luxury segment, it will be introducing

dditional facilities of health club, spa and movie lounge.a

News Update

Regulatory

India Russia aiming to boost bilateral pharmaceutical trade

India and Russia have come together to liberalize the registration process of new drugs to

improve bilateral trade between the countries. The countries are expected to sign a

memorandum of understanding (MoU) for a quicker and easier registration for drugs andpharmaceutical products. This comes after the MoU the countries had signed in 2010 for

ooperation in pharma trade and industry for which both are currently working towardsc

setting up a task force to exchange knowledge and views.

Indian pharmaceutical industry is trying to bank upon the heavily import dependent Russian

pharmaceutical market. With the new MoU, it is expected to do away with the lengthy




process and non‐acceptance of clinical trials data generated by other countries whileregistering their drugs in Russian pharmaceutical market.

Chhattisgarh implements strict measures against fake drugs

The Chhattisgarh Food Drug Control Administration (FDCA) has taken a major step to

control the circulation of spurious and substandard drugs along with controlling red tapismfor various processes prevalent in pharmaceutical industry. In regard to spurious and

substandard drugs circulating in the market, FDCA plans to publish the data online with their

etails.batch numbers and other relevant d

The government has put in place a unique software Extended Laboratory Node through

National Informatics Centre (NIC) to fulfill its plan. The Chhattisgarh FDCA initiated such a

move taking a cue from the Gujarat government that is currently aiding Chhattisgarh forsuccessful implementation of the project.

News Update

Expansion Plans

AHLL to invest for expansion in number of clinics

The subsidiary unit of Apollo Hospitals Enterprise Ltd., Apollo Health and Lifestyle Ltd.(AHLL) is in plans to raise the number of its branded healthcare clinics. It is planning for a 5‐

fold increase from the current 90 such operating clinics in the next 3‐5 years. The clinics will

e spread across the metro and other prominent cities of the country for which AHLL has set baside INR 2.5 bn.

The clinics that are being planned by the group will be owned by the company unlike the

franchise mode of operation of the currently operative 90 clinics. Such a decision has beenplanned strategically in order to keep an eye on the quality of healthcare service being meted

ut to its patients. With the rise in the number of clinics, the Apollo group is expecting aevenue surge from its Mar 2012 revenue of INR 0.36 bn to INR 5 bn.

or

Industry Expert Speak

SightLife partners with L V Prasad Eye Institute – Dr. Gullapalli N Rao, Chairman of L V

Prasad Eye Institute

“The Ramayamma International Eye Bank will be the first centre in the Asia Pacific region tohave taken a step in this direction to make the pre‐cut donor corneas available to all




interested corneal surgeons. This not only reduces the overall cost of the surgery for both theatients and the surgeons but also standardizes the procedure.”p

BITS Pilani comes up with 1st indigenous low cost glucometer - Suman Kapur,

Biological Sciences Professor and Chief Developer of diagnostic tool, BITS -Pilani

"The final evaluation took place on August 6 and we have been given the go‐ahead to create

the prototype which will be ready latest by December. Most such devices need to undergomulti‐centre trials. So once the prototype is delivered, ICMR will commission studies in

various labs to confirm the technology. Once through, we will either produce the machine

ourselves or transfer the technology to a third party for mass production and introductioni

nto the market."

Chhattisgarh implements strict measures against fake drugs - K Subramanian, Food

Safety Commissioner

for

Chhattisgarh

and

Controller

Food

and

Drugs

Administration

"We have already started uploading the existing data and by Nov 15 we will complete the

rocess. Subsequently, the data would be updated on day to day basis and our services woulde launched by Dec."

pb

Transaction Detail (Aug – Sep 2012)

Date

Buyer

Target

Deal Size

(INR mn)

%

stake

Deal

Status

Type of

Transaction

2 t 5th Oc2012

Fidelity IndiaCapital

TrivitronHealthcare

4000 35‐40 Planned Private Equity

2 t 2nd Oc2012

Dr. Reddy'sLaboratories

OctoPlus N.V. 1930 100 Planned Acquisition

1 t 7th Oc2012

MylanLaboratories

SMS

Pharmaceuticals’Vishakhapatnamlocated

m ganufacturin

1730 N.A. Completed Acquisition

27th Sep

2012

Norwest Venture

Partners

Thyrocare

Technologies1200 10 Completed Private Equity




12th Sep

2012

Avigo Capital

Partners

Super Religare

Laboratories2,916.79 N.A. Planned Private Equity

12th Sep

2012

IndoUS

VenturePartners

Vyome

Biosciences Pvt Ltd.

185 N.A. Planned Private Equity

11th Sep2012

Norwest

VenturePartners

Thyrocare

TechnologiesLtd

1166.71 10 Planned Private Equity

5th Sep

2012

Norwest

Venture

Partners

NationWide

Primary

He ealthcarS .ervices Pvt. Ltd

250 N.A. Completed Private Equity

30 gth Au2012

Hospira

OrchidChemicals and

P sharmaceuticalLtd.

Penicillin andPenem API

business

11125.89 100 Completed Acquisition

29 gth Au2012

Pfizer

Strides ArcolabInjectable Drug

Unit 94600 100 Planned Acquisition

23 grd Au

2012

India

InnovationFund

&Indian Angel

Network

Consure Medical N.A. N.A. Completed Private Equity

21st Aug

2012

India Equity

PartnersAxiss Dental N.A. N.A. Planned Private Equity

13 gth Au2012

Somerset Indus

CapitalPartners

Express ClinicsPvt. Ltd.

N.A. N.A. Completed Private Equity

13 gth Au2012

Goldman Sachs

&New Enterprise

Associates

Nova MedicalCentres

2969.35 N.A. Completed Private Equity




13 gth Au

2012

SunPharmaceutical

Industries Ltd.

Taro

PharmaceuticalIndustries

32,552.9 34 Planned M&A

Annual Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7

Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0

Dr. Reddy’s Laboratories(DRL)

69,441.00 70,277.00 74,693.00 96,737.4

GlaxosmithKlineConsumer Healthcare

Ltd.

19,757.6 23,693.3 27,688.6 28,857.3

Glenmark Pharmaceuticals Ltd.

21,241.20 25,291.30 29,490.70 40,206.4

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5

Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1

Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0

Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Ranbaxy Laboratories

Ltd.75,970.40 89,607.70 101,614.1 117,153.2

Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9

Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1




Sun Pharmaceuticals

Industries Ltd.42,723.00 38,086.30 57,214.30 80,056.6

Torrent PharmaceuticalsLtd.

16,306.60 19,160.40 22,264.80 26,959.2

Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0

Annual Financial Results – Income (INR mn) - Major Healthcare

Companies

Companies F Y ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0

Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9

Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4

Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0

Dr. Reddy’s Laboratories

(DRL) ‐5,168.00 1,068.00 11,040.00 14,262.1

GlaxoSmithKline ConsumerHealthcare Ltd.

2,327.8 2,998.5 3,552.1 3,765.6

Glenmark Pharmaceuticals

Ltd.1,916.60 3,244.70 4,532.10 4,603.5

Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7


Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0




Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6

Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4

Sun PharmaceuticalsIndustries Ltd.

18,177.30 13,510.80 18,160.60 25,872.5

Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4

Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1

Quarterly Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies

Jul-Sep

2011

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Biocon Ltd. 5,084.40 5,171.90 5,892.2 5,770.0

Blue Star Ltd. N.A. 5,896.9 N.A. N.A.

Cadila Healthcare Ltd. 12 0,196.4 13,524.60 14 .9,633 15 .0,161

Cipla Ltd. N.A. 17,580.00 N.A N.A.

Dabur India Ltd. 12,623.30 14,526.80 13,858.3 14,620.0


22,678.00 27,692.00 26,584.0 25,406.0

GlaxoSmithKline Consumer

Healthcare Ltd.7,200.7 6,854.0 8,608.7 7,869.6

Glenmark PharmaceuticalsLtd.

10,554.50 10,310.90 10,751.2 10,404.1

Jubilant life Sciences Ltd. 10,480.80 10,871.70 12,235.9 12,358.9

Lupin Ltd. 17,416.6 17,917.0 20,063.7 22,191.5




Nestle India Ltd. 19,631.00 19,633.2 20,558.7 19,865.8


Piramal Enterprises Ltd. 4,775.80 5,518.30 8,858.0 7,102.9

Ranbaxy Laboratories Ltd. 20 .3,955 37 .1,923 36,954.0 31 .6,740

Siemens India Ltd. N.A. N.A. 37 2601.43 N.A.

Strides Arcolab Ltd 7,693.10 6,864.7 5,274.7 5,082.9

Sun PharmaceuticalsIndustries Ltd.

18,946.00 21,451.30 23,299.3 26,581.4

Torrent Pharmaceuticals Ltd 6,833.3 6,965.9 6,686.8 7,356.0

Wockhardt Ltd. 11,105.30 12,086.70 12,413.90 14,258.2

Companies

Jul-

Sep

2011 Oct

-

Dec

2011 Jan

-

Mar

2012 Apr

-

Jun

2012

Biocon Ltd. 857.0 848.50 978.0 790.0

Blue Star Ltd. N.A. (327.6) N.A. N.A.

Cadila Healthcare Ltd. 1,0 026.8 1,492.10 1,708.8 1, 9947.

Cipla Ltd. N.A. 2,699.10 N.A. N.A.

Dabur India Ltd. 1,738.6 1,728.20 1,705.1 1,494.0


3,078.0 5,130.0 3,427.0 3,360.0

GlaxoSmithKline ConsumerHealthcare Ltd.

1,030.3 591.0 1,319.7 1,066.0

Glenmark PharmaceuticalsLtd.

558.6 461.20 1,482.7 782.8

Jubilant life Sciences Ltd. 793.6 ‐783.90 ‐635.3 50.1

Quarterly Financial Results – Income (INR mn) - Major Healthcare

Com anies




Lupin Ltd. 2,668.70 2,350.60 1,556.4 2,803.9

Nestle India 2,611.80 2,308.30 2,757.3 2,459.7


Piramal Enterprises Ltd. 524.3 85.2 ‐386.8 40.8

Ranbaxy Laboratories Ltd. ‐4,645.8 ‐29 .7,827 12,467.6 ‐5,857.3

Siemens India Ltd. N.A. N.A. 3,040.0 N.A.

Strides Arcolab Ltd 464.7 684.1 6,420.7 904.8

Sun Pharmaceuticals

Industries Ltd.5,977.4 6,683.0 8202.1 7,955.5

Torrent Pharmaceuticals Ltd 999.9 831.8 ‐16.5 1,018.5

Wockhardt Ltd. 1,275.80 2,128.10 ‐1,916.4 3,779.7

* denotes a change in financial year

Events Calendar

Indian Medical Tourism Conference and

Alliance 2201

Date: 2

nd –enue:

3rd Nov 2012V The Park Hotel, HyderabadOrganizer: IMTCA, ONE HealthCareTM Worldwide

l Tourismand Centre for medica

Research.comWebsite: http://www.imtca

Contact No.: +91‐40‐64640323

E‐mail: [email protected]

Problem Solving Approach in Children with

Cerebr Pal alsy

ate: 18

D th Nov, 2012Venue: Me um, Prayag Sangeet Samiti,

C

hta Auditori

Organize

ivil Lines, Allahabad

r: SamveWebsite:

dna

http://www.samvednatrust.com Contact Pers hon: Mr. Alok SingContact No.: +91 9453039213


mailto:[email protected]












http://www.samvednatrust.com/






















5 Days Hands-on Workshop on Molecular

Biotec o and ormatics hn logy Bioinf

Date: 19

th –enue:

23rd Nov 2012V PuneOrganizer: International Center for Stem Cells,

Cancer and Biotechnology (ICSCCB),Pune

Website: g/workshopsht /tp://www.icsccb.or Contact r.Contact 8

Pe Mohan Singhrson: Prof. D Sheo No.: +91 95450 9202

E‐mail: [email protected] or [email protected]

Raps 2012: International Conference on Recent

Advances a al Sciences in Ph rmaceutic

Date:

22

n

Venue: Wd – 24th Nov, 2012arangal, Andhra Pradesh

Website: http://tinyurl.com/8fwmpb4

Clinical

Trials

in

Southeast

Asia

(CTSE)

2012

Date: 23rd NVenue: T

ov 2012

Organize

he Sahara Star Hotel, Mumbair: Clini

Website:

cal Research

http://www.ssiconnects.org Contact Person: Amita Shah

No.: + 91 976 916 897E-mail: [email protected]

Contact 2

5th

National

Conference

of

AIDS

Society

of

India

Date: 23rd –Venue: V Bangalore

25th Nov, 2012

Organize

ivanta by Taj Yeshwantpur,r: AIDS a

Website:

Society of Indi

http://www.asi‐asicon.com Contact Person: Dr. I. S. Gi

Fax No.:

ladaContact No.: +91 22 23061616

+91 22 23000016

E-mail: [email protected] / [email protected]


http://www.icsccb.org/workshops/
















http://tinyurl.com/8fwmpb4






http://www.ssiconnects.org/











http://www.asi-asicon.com/






































Research on India (ROI) is a leading source for market research on various sectors in Indiahat offers premium research content from worldwide publishers of market researcht

reports.

Contact us:

mW: https://www.researchonindia.co

; International: +91 (33) 4027 6214/5TE

: India (Toll Free): 1800 102 1133: [email protected]

Connect with Us

Disclaimer: This

monthly

update

is

published

for

general

information

only

based

on

press

rticles and company releases. Research on India has not independently verified any of nformation and is not responsible for any loss or damage arising from use of this document. a

i


http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

https://twitter.com/ResearchOnIndia

http://www.facebook.com/researchonindia

Healthcare Sector in India Monthly Update October 2012

Documents

Transcript of Healthcare Sector in India Monthly Update October 2012